HRTX — Heron Therapeutics Share News
0.000.00%
Last trade - 00:00- $57.49m
- $158.52m
- $154.90m
U.S. STOCKS ON THE MOVE-Tesla, Microsoft, BlackBerry
U.S. STOCKS ON THE MOVE-Netfilx, DuPont, Baker Hughes
U.S. STOCKS ON THE MOVE-Gold miners, TE Connectivity, Amphenol
U.S. STOCKS ON THE MOVE-Walgreens, Netflix, DuPont
Heron Therapeutics rises after FDA nod for expanded use of pain relief drug
Brief: Heron Therapeutics Announces FDA Approval Of Zynrelef® Indication Expansion To Include Additional Orthopedic And Soft Tissue Procedures
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
U.S. STOCKS ON THE MOVE-DoorDash, Harpoon Therapeutics, Heron Therapeutics
Heron Therapeutics gains on pact to expand sales network for pain relief drug
Brief: Heron Therapeutics Announces Partnership With Crosslink Life Sciences To Expand Promotional Effort For Zynrelef®, First And Only Non-Opioid Dual Acting Local Anesthetic For Post-Operative Pain
Brief: Heron Therapeutics Receives A Paragraph IV Certification Notice From Mylan Pharmaceuticals Inc.
Heron Therapeutics rises on 2023 oncology sales forecast raise
Heron Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Heron Therapeutics Files For Resale Of Up To 21.9 Million Shares Of Common Stock - Sec Filing
Brief: Heron Therapeutics Q2 net product sales USD 31.762 million
Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview